HF prevalence and evolution of HF in DM II patients at high risk

Trial Identifier:	D1843R00313
Sponsor:	AstraZeneca
NCTID::	NCT04482283
Start Date:	July 2020
Primary Completion Date:	November 2024
Study Completion Date:	November 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Greece, D1843R00313	Athens, D1843R00313, Greece, 10676
Greece, D1843R00313	Athens, D1843R00313, Greece, 10676
Greece, D1843R00313	Athens, D1843R00313, Greece, 10676
Greece, D1843R00313	Athens, D1843R00313, Greece, 10676
Greece, D1843R00313	Athens, D1843R00313, Greece, 10676
Greece, D1843R00313	Athens, D1843R00313, Greece, 10676
Greece, D1843R00313	Athens, D1843R00313, Greece, 10676
Greece, D1843R00313	Athens, D1843R00313, Greece, 10676
Greece, D1843R00313	Athens, D1843R00313, Greece, 10676
Greece, D1843R00313	Athens, D1843R00313, Greece, 10676

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company